MetaCap

Satellos Bioscience (MSLE) vs Zentalis Pharmaceuticals (ZNTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zentalis Pharmaceuticals (ZNTL) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 1.5% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -98.2% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $120.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MSLE-5.33%ZNTL+1.49%
+413%+193%-27%
Nov 21, 20251 yearNov 20, 2026
MSLE-53.27%ZNTL-98.25%
+18%-43%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MSLE versus ZNTL key metrics
MetricMSLEZNTL
Share price$5.68$1.36
Market cap$120.51M$133.64M
1-day change-2.07%0.00%
YTD return-3.40%+0.74%
1-year return-5.33%+1.49%
5-year return-58.48%-98.21%
EPS (TTM)$-2.12$-1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-24.87M$-137.06M
52-week high$13.40$6.95
52-week low$5.44$1.30
Distance from 52-week high-57.60%-80.43%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+325.53%+447.06%
Average volume51.19K1.26M
Shares outstanding21.22M98.27M
Employees18106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Satellos Bioscience

MSLE stock →

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

About Zentalis Pharmaceuticals

ZNTL stock →

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

MSLE vs ZNTL FAQ

Which is bigger, Satellos Bioscience or Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $120.51M for Satellos Bioscience (MSLE).

Which stock has performed better over the past year, MSLE or ZNTL?

ZNTL returned +1.49% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.

Are Satellos Bioscience and Zentalis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons